Cartesian Therapeutics Inc. (RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, has a clinical trial catalyst to watch in the coming months.
The company's lead drug candidate is DESCARTES-08, currently under a phase IIb trial in patients with generalized myasthenia gravis.
Generalized myasthenia gravis is a debilitating autoimmune disease affecting over 60,000 people in the U.S. *It is caused by autoantibodies targeting components of the neuromuscular junction (Source: NLM).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.